Sponsored Education Lunch Hub: Bayer - Finerenone: A new treatment for chronic kidney disease in type 2 diabetes – from evidence to practice
Tracks
Stream 6
Stream 7
Stream 8
Stream 9
Thursday, August 24, 2023 |
12:20 PM - 1:05 PM |
Exhibition Hall - Education Hub 2 |
Details
Please join A/Prof Sarah Glastras as she discusses the clinical evidence for finerenone and which patients may benefit.
Speaker
Prof Sarah Glastras
Endocrinologist
Royal North Shore Hospital
Finerenone: A new treatment for chronic kidney disease in type 2 diabetes – from evidence to practice
Biography
A/Prof Sarah Glastras is a clinician researcher who works as a Staff Specialist in Endocrinology at the Royal North Shore Hospital, Sydney and is an academic Associate Professor at the University of Sydney. She also consults at the Northern Sydney Endocrine Clinic. She is an NHMRC Fellow undertaking basic science research in the area of foetal programming of chronic disease, and she is a principal researcher in a major NHMRC funded population based project in gestational diabetes and pregnancy outcomes. She runs many clinical studies in the areas of diabetes and obesity. She currently chairs the Diabetes Clinical Advisory Group within the Northern Sydney Local Health District and is the Training Lead of the TTRA-funded Australian Centre for Accelerating Diabetes Innovations (ACADI).